ResearcherUniversity of ChicagoNo recent work listed
Kevin King Roggin
Matched on ORCID iD 0000-0002-6084-2045; OpenAlex author ID A5084810345. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper
Papers 6
- Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1541-7786.mcr-18-0531↗
- Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Co-author DOI 10.1002/jso.24872↗
- The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. Co-author DOI 10.1016/j.jgo.2018.03.002↗
- Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? Co-author DOI 10.1016/j.surg.2017.09.022↗
- Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2016.11.039↗
- Paraduodenal pancreatitis (groove pancreatitis) mimicking pancreatic adenocarcinoma. Last author DOI 10.1016/j.cgh.2011.07.011↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hedy Lee Kindler · 3 shared papers, 2018–2019 · strength 0.24
- Paper The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pat… DOI 10.1016/j.jgo.2018.03.002↗
- Paper Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. DOI 10.1002/jso.24872↗
- Paper Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. DOI 10.1158/1541-7786.mcr-18-0531↗
- Marshall S. Baker · 3 shared papers, 2017–2018 · strength 0.21
- Paper Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. DOI 10.1002/jso.24872↗
- Paper Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? DOI 10.1016/j.surg.2017.09.022↗
- Paper Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. DOI 10.1016/j.amjsurg.2016.11.039↗
- Marina Talamonti · 3 shared papers, 2017–2018 · strength 0.21
- Paper Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. DOI 10.1002/jso.24872↗
- Paper Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? DOI 10.1016/j.surg.2017.09.022↗
- Paper Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. DOI 10.1016/j.amjsurg.2016.11.039↗
- Robert Marsh · 3 shared papers, 2017–2018 · strength 0.21
- Paper Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. DOI 10.1002/jso.24872↗
- Paper Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? DOI 10.1016/j.surg.2017.09.022↗
- Paper Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. DOI 10.1016/j.amjsurg.2016.11.039↗
- Richard A. Prinz · 2 shared papers, 2017–2018 · strength 0.14
- David J. Bentrem · 2 shared papers, 2017–2018 · strength 0.14
- Shuang Qin Zhang · 1 shared paper, 2018 · strength 0.09
- William Dale · 1 shared paper, 2018 · strength 0.09
- Andrew J. Benjamin · 1 shared paper, 2018 · strength 0.09
- Jeffrey B. Matthews · 1 shared paper, 2018 · strength 0.07
- Mitchell C. Posner · 1 shared paper, 2018 · strength 0.07
- Daniel V.T. Catenacci · 1 shared paper, 2018 · strength 0.07
- Blasé N. Polite · 1 shared paper, 2018 · strength 0.07
- Kevin P. White · 1 shared paper, 2019 · strength 0.07
- Isabel Romero‐Calvo · 1 shared paper, 2019 · strength 0.07
- Nicholas R. Suss · 1 shared paper, 2018 · strength 0.07
- Waseem Lutfi · 1 shared paper, 2017 · strength 0.06
- Olga Kantor · 1 shared paper, 2017 · strength 0.06
- Sharif R. Nankoe · 1 shared paper, 2012 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.